T2 Biosystems Awarded Top Honor as ‘Most Promising Company’ at Personalized Medicine World Conference 2014

T2 Biosystems Awarded Top Honor as ‘Most Promising Company’ at Personalized Medicine World Conference 2014

January 30, 2014

— T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced that it has been awarded top honor as the “Most Promising Company” at the 2014 Personalized Medicine World Conference held in Mountain View, CA, January 27-28. T2 Biosystems was chosen from a group of 22 competitors in recognition of its strong business model and team, as well as its innovative T2MR technology. T2MR technology can be applied in the future to detect the presence of multiple diseases or conditions, including sepsis and trauma, and it powers the Company’s flagship T2Candida test, which is under investigation for the rapid detection of five species of Candida. The T2Candida test is designed to provide low limits of detection, (as low as 1 CFU/mL) and rapid results, typically in hours instead of days. T2Candida is currently in a pivotal clinical trial with results expected in the first half of 2014.

“It is a tremendous honor to be chosen by both a distinguished panel of judges and our peers. T2MR has the potential to truly disrupt the current standard of care, as exemplified by our flagship test, T2Candida. We believe T2Candida has the potential to significantly impact the way Candida is detected and managed in septic patients by rapidly providing physicians with information to aid in the selection of appropriate therapy,” said John McDonough, President and CEO, T2 Biosystems. “This test could meaningfully and positively impact clinical outcomes and hospital costs associated with sepsis, and we believe these were some of the many reasons we received the ‘Most Promising Company’ award.”

The competitors were selected for their disruption to the current standard-of-care, both in cost and effectiveness, strength of team and ability to execute, barriers to competition and strength of intellectual property and expected financial returns for investors. Judges consisted of a panel of venture capitalists and industry representatives, and input from the audience was considered in the final vote.

The T2Candida test is currently intended for Investigational Use Only. The performance characteristics of this product have not yet been established.

About T2 Biosystems

T2 Biosystems is setting a new standard in clinical diagnostics powered by T2MR, the world’s first direct detection technology that is designed to deliver superior sensitivity at unmatched speed to guide more effective clinical decision-making. T2 Bio’s pipeline of molecular diagnostic and hemostasis products is focused on conditions where rapid and accurate results will have the greatest impact on patients’ lives and healthcare costs. The Company’s lead products, T2Candida and T2Bacteria, are designed to identify life-threatening pathogens associated with sepsis directly from whole blood, potentially up to 25-times faster than blood culture.

T2MR and T2Candida are registered trademarks of T2 Biosystems.

T2HemoStat and T2Bacteria are trademarks of T2 Biosystems.

Read more here: http://www.heraldonline.com/2014/01/30/5628615/t2-biosystems-awarded-top-honor.html#storylink=cpy